Xeris Biopharma Holdings, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Xeris Biopharma Holdings, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Xeris Biopharma Holdings, Inc. do? Business model and key facts
Get the full picture of Xeris Biopharma Holdings, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 394
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Stocks related to Xeris Biopharma Holdings, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Xeris Biopharma Holdings, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Xeris Biopharma Holdings, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
